1 result for "Evan W. Rogers"
Add this URL to any RSS reader. Updated daily.
Macrocyclic Compounds, SRC MET Inhibitor, Cancer Treatment
USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.
Routine
Notice
Intellectual Property
Get alerts for "Evan W. Rogers"
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Browse Categories
Agriculture & Food Safety
73
AI Regulation
3
Banking & Finance
412
Consumer Protection
89
Courts & Legal
411
Data Privacy & Cybersecurity
90
Defense & National Security
53
Education
55
Energy
100
Environment
152
Gaming
2
Government & Legislation
430
Healthcare
15
Healthcare & Life Sciences
375
Immigration
10
Insurance
76
Labor & Employment
134
Pharma & Drug Safety
21
Professional Licensing
8
Real Estate & Housing
78
Securities & Markets
154
Tax
78
Telecom & Technology
47
Trade & Sanctions
141
Transportation
91
Get alerts for "Evan W. Rogers"
We'll email you when new changes match "Evan W. Rogers".
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.
You're subscribed!